Trisalus Life Sciences Inc (TLSI) Stock Price, Quote & News

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde...

Industry: Medical Devices

Sector: Healthcare

Phone: (888) 321-5212

Website: trisaluslifesci.com

Address:

6272 West 91st Avenue, Westminster, United States

StockScanners Aug. 19 at 12:46 AM

$TLSI reached 4.95

0 · Reply

StockScanners Aug. 16 at 2:09 AM

$TLSI keep watch if this holds above 4.15

0 · Reply

outlawinvestor1 Aug. 15 at 1:25 AM

$RNXT just listened to the q2 er call. i have to say i am more impressed with the company/leadership than i was previously. i didn't have a good initial impression of the ceo and doubted the mgmt team/bod. the mgmt team and bod seem to be run by an academic clinician (ramtin agah) - while they're usually smart and know the clinical unmet need, they're not typically good at running businesses. i thought the ceo came off as a bit of a show boat before, but really appreciated how confident and knowledgeable he was on today's call. i initially invested based on a belief in the tech as well as the initial data readout. however, now, i think the ceo and the team that they're developing are actually competent and could really translate this tech addressing a real medical unmet need into a real business. in addition, i'm always happy to see when mgmt buys their own stock and it's not just given using inducement grants. Based on today's q2 update and call, I'm confident in building a larger position in this opportunity. $NVCR $DCTH $TLSI

0 · Reply

AccuRoger Aug. 12 at 2:13 PM

$TLSI This is a technical podcast describing individual Case Studies only. The emphasis is using TriNav for Liver Radioembolization. Nelitolimod gets a positive mention. The speaker is clear regarding the benefits of using the TLSI PEDD system for liver access. Enjoy. https://www.youtube.com/watch?v=92jR6PCvJIM&pp=0gcJCf8Ao7VqN5tD

0 · Reply

AccuRoger Aug. 9 at 2:38 PM

$TLSI New PEDD article published regarding Thyroid treatment success. This information should be revealed by management this week. Quote The present study demonstrates that PED-TAE is safe and effective for the treatment of large goiters, with a significant volume reduction of the nodule(s) and of the thyroid gland. The technique's safety profile and rapid symptom relief underscore its clinical potential in improving patients' QoL. Prospective research is warranted to establish long-term efficacy… https://academic.oup.com/jes/article/9/9/bvaf117/8196950

1 · Reply

AccuRoger Jul. 26 at 4:28 PM

$TLSI This recently published article is odd because it describes a trial that ended in 2018. It looks as though they simply replaced the OLD name, SD-101, with the new name, Nelitolimod. It may presage the start of a confirmation trial; but, who is gonna pay? Enjoy the mystery. https://pubmed.ncbi.nlm.nih.gov/40711475/

0 · Reply

XkaliburTrading Jul. 24 at 10:49 PM

$TLSI https://www.benzinga.com/pressreleases/25/07/b46619599/trisalus-life-sciences-announces-expiration-and-results-of-exchange-offer-and-consent-solicitation

0 · Reply

AccuRoger Jul. 22 at 6:33 PM

$TLSI Here is a recent UVEAL Melanoma review article that covers the challenges and the new treatment trends. Nelitolimod (SD-101) Phase I/II results are summarized with positive commentary. I would like to see further development by Trisalus as PEDD delivers less toxicity for lower cost and encouraging results for the many Uveal patients whose genetic factors do not match with the Standard of Care option currently available. https://www.mdpi.com/2077-0383/14/14/5137

0 · Reply

jesys Jul. 17 at 7:24 PM

$TLSI 🚀🚀🚀🚀

0 · Reply

Joepeoples77 Jun. 23 at 11:35 PM

$TLSI what’s this conversion mean?

1 · Reply

TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:01 PM EDT - 12 days ago

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

Aug 11, 2025, 8:00 AM EDT - 13 days ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

Jul 30, 2025, 4:05 PM EDT - 25 days ago

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 26 days ago

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

Jul 24, 2025, 5:58 PM EDT - 4 weeks ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

Jun 23, 2025, 5:30 PM EDT - 2 months ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

Jun 4, 2025, 8:00 AM EDT - 2 months ago

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

May 30, 2025, 7:00 AM EDT - 3 months ago

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 15, 2025, 6:45 PM EDT - 3 months ago

TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 7:00 AM EDT - 3 months ago

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

May 12, 2025, 4:30 PM EDT - 3 months ago

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

Apr 30, 2025, 8:00 AM EDT - 4 months ago

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

Mar 30, 2025, 8:02 AM EDT - 5 months ago

TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks

Mar 27, 2025, 2:02 PM EDT - 5 months ago

TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 5 months ago

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 5 months ago

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

Mar 6, 2025, 8:00 AM EST - 6 months ago

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

Feb 3, 2025, 4:05 PM EST - 7 months ago

TriSalus Life Sciences Announces Key Appointments to Board of Directors

Feb 3, 2025, 8:00 AM EST - 7 months ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

Jan 23, 2025, 8:00 AM EST - 7 months ago

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

Jan 9, 2025, 8:00 AM EST - 8 months ago

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

Dec 24, 2024, 11:29 AM EST - 8 months ago

TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut

Nov 14, 2024, 10:22 AM EST - 10 months ago

TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:00 AM EST - 10 months ago

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 10 months ago

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

Nov 7, 2024, 7:00 AM EST - 10 months ago

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

Oct 31, 2024, 8:00 AM EDT - 10 months ago

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Oct 14, 2024, 4:05 PM EDT - 11 months ago

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 26, 2024, 7:00 AM EDT - 11 months ago

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

Sep 23, 2024, 7:00 AM EDT - 11 months ago

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Aug 15, 2024, 2:33 PM EDT - 1 year ago

TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 8:00 AM EDT - 1 year ago

TriSalus Reports Q2 2024 Financial Results and Business Update

Aug 1, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Jul 1, 2024, 4:00 PM EDT - 1 year ago

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

Jun 26, 2024, 5:45 PM EDT - 1 year ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

Jun 25, 2024, 3:17 PM EDT - 1 year ago

TriSalus Life Sciences: Falling Despite Moving Forward Into The Market

Jun 3, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

May 24, 2024, 6:05 AM EDT - 1 year ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

May 15, 2024, 11:40 AM EDT - 1 year ago

TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript

May 15, 2024, 8:00 AM EDT - 1 year ago

TriSalus Reports Q1 2024 Financial Results and Business Update

May 7, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

May 6, 2024, 4:58 PM EDT - 1 year ago

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

Apr 30, 2024, 4:35 PM EDT - 1 year ago

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

Apr 1, 2024, 10:56 AM EDT - 1 year ago

TriSalus Life Sciences, Inc. (TLSI) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 8:00 AM EDT - 1 year ago

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Mar 26, 2024, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

Mar 21, 2024, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

Mar 11, 2024, 5:15 PM EDT - 1 year ago

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

Mar 7, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

StockScanners Aug. 19 at 12:46 AM

$TLSI reached 4.95

0 · Reply

StockScanners Aug. 16 at 2:09 AM

$TLSI keep watch if this holds above 4.15

0 · Reply

outlawinvestor1 Aug. 15 at 1:25 AM

0 · Reply

AccuRoger Aug. 12 at 2:13 PM

0 · Reply

AccuRoger Aug. 9 at 2:38 PM

1 · Reply

AccuRoger Jul. 26 at 4:28 PM

0 · Reply

XkaliburTrading Jul. 24 at 10:49 PM

$TLSI https://www.benzinga.com/pressreleases/25/07/b46619599/trisalus-life-sciences-announces-expiration-and-results-of-exchange-offer-and-consent-solicitation

0 · Reply

AccuRoger Jul. 22 at 6:33 PM

0 · Reply

jesys Jul. 17 at 7:24 PM

$TLSI 🚀🚀🚀🚀

0 · Reply

Joepeoples77 Jun. 23 at 11:35 PM

$TLSI what’s this conversion mean?

1 · Reply

DonCorleone77 May. 30 at 11:36 AM

$TLSI TriSalus Life Sciences appoints Patience as Chief Financial Officer TriSalus Life Sciences announces the appointment of David Patience as Chief Financial Officer, effective July 1, 2025. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice President of Finance for TriSalus, will serve as acting Chief Financial Officer during the transition period. Young remains available to the Company to support an orderly transition.

0 · Reply

mikesterz7 May. 15 at 11:41 AM

$TLSI Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD

0 · Reply

Thestocktraderhubzee May. 15 at 11:02 AM

$TLSI TriSalus Life Sciences Q1 EPS $(0.39) Misses $(0.23) Estimate, Sales $9.17M Beat $9.04M Estimate

0 · Reply

Joepeoples77 May. 13 at 6:44 PM

$TLSI not expecting any earth shattering report. They’ve already announced that their revenue expectations are $9.2 million which is below the 9.4 million estimate.

0 · Reply

Joepeoples77 May. 2 at 1:34 PM

$TLSI why they like to give a preliminary earnings beat and then dilute more? Won’t be long and there will be a suit filed imo

0 · Reply

FE123 Apr. 30 at 1:54 PM

$TLSI 5 .5 Million shares Offered at $4

0 · Reply

G101SPM Apr. 29 at 12:09 PM

#DILUTION $EC obtains authorization to execute a loan agreement with an international bank for $500 mln $EZPW reports Q2 results; completed $300.0 million private offering of senior notes, the Company’s largest financing transaction to date $PLX files for $100 mln mixed securities shelf offering $TLSI files for 251,885 share common stock offering by selling shareholders

0 · Reply

Doozio Apr. 16 at 8:11 PM

Wen $TLSI ? 2mro or next week with scrabbled with a 🦄👑? Da 🧠 returns wen only SKWD 🐑 remain?

0 · Reply

Doozio Apr. 16 at 5:24 PM

chop chop huckleberries out of 🐑 amania $TLSI a 🧠 shall return.

1 · Reply

Doozio Apr. 9 at 3:29 PM

$TLSI Druck name that hasn’t OD’d on DRUGzzzz like bahhhh rest of XBI.

1 · Reply

NVDAMillionaire Mar. 29 at 1:45 AM

Digging the innovative PEDD tech. Looks like TriSalus could disrupt solid tumor treatment. Clinical trials in pancreatic cancer showing promise. Watching closely for Q2 data. Might take a small position if momentum builds. $TLSI looking interesting. clear overview of current strategy: https://beyondspx.com/article/trisalus-life-sciences-nasdaq-tlsi-revolutionizing-solid-tumor-treatment-through-advanced-delivery-and-innovative-immunotherapy

0 · Reply

JarvisFlow Mar. 28 at 3:18 PM

Canaccord Genuity has updated their rating for TriSalus Life Sciences ( $TLSI ) to Buy with a price target of 11.

0 · Reply

Market Cap	191.09M
Revenue (ttm)	29.43M
Net Income (ttm)	-30.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.11%
Debt to Equity Ratio	-1.66

Volume	166,400
Avg Vol	109,552
Day's Range	N/A - N/A
Shares Out	37.84M
Stochastic %K	88%
Beta	0.48
Analysts	Strong Sell
Price Target	$11.31